NCT04116840View on ClinicalTrials.gov

Single Ascending Dose Trial to Evaluate the Safety, Tolerability, PK, and PD of MT1002 for Injection

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 29, 2019

Primary Completion Date

August 1, 2019

Study Completion Date

November 27, 2019

Conditions
Healthy
Interventions
DRUG

MT1002 for injection

Study drug will be administered by an intravenous bolus dose followed by an infusion of 4 hours.

Trial Locations (1)

21201

Pharmaron CPC, Inc., Baltimore

All Listed Sponsors
lead

Shaanxi Micot Pharmaceutical Technology Co., Ltd.

INDUSTRY

NCT04116840 - Single Ascending Dose Trial to Evaluate the Safety, Tolerability, PK, and PD of MT1002 for Injection | Biotech Hunter | Biotech Hunter